About Abbisko Therapeutics
Abbisko Therapeutics is a company based in Shanghai (China) founded in 2016.. Abbisko Therapeutics has raised $263 million across 4 funding rounds from investors including CICC, The Carlyle Group and Warburg Pincus. The company has 226 employees as of December 31, 2024. Abbisko Therapeutics operates in a competitive market with competitors including Enliven Therapeutics, Nuvalent, Nura Bio, NewAmsterdam Pharma and Skyhawk Therapeutics, among others.
- Headquarter Shanghai, China
- Employees 226 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Abbisko Cayman Limited
-
Annual Revenue
$70.36 M (USD)2494.53as on Dec 31, 2024
-
Net Profit
$3.95 M (USD)0as on Dec 31, 2024
-
EBITDA
$275.54 K (USD)0as on Dec 31, 2024
-
Total Equity Funding
$263 M (USD)
in 4 rounds
-
Latest Funding Round
$123 M (USD), Series D
Jan 08, 2021
-
Investors
CICC
& 15 more
-
Employee Count
226
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Abbisko Therapeutics
Abbisko Therapeutics is a publicly listed company on the HKEX with ticker symbol 2256 in Hong Kong, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Funding Insights of Abbisko Therapeutics
Abbisko Therapeutics has successfully raised a total of $263M across 4 strategic funding rounds. The most recent funding activity was a Series D round of $123 million completed in January 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Series D — $123.0M
-
First Round
First Round
(05 Feb 2017)
- Investors Count 16
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan, 2021 | Amount | Series D - Abbisko Therapeutics | Valuation | The Carlyle Group | |
| Mar, 2020 | Amount | Series C - Abbisko Therapeutics | Valuation | Temasek | |
| Mar, 2019 | Amount | Series B - Abbisko Therapeutics | Valuation | Qiming Venture Partners |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Abbisko Therapeutics
Abbisko Therapeutics has secured backing from 16 investors, including venture fund and institutional investors. Prominent investors backing the company include CICC, The Carlyle Group and Warburg Pincus. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity investments are directed toward multiple sectors.
|
Founded Year | Domain | Location | |
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Founded Year | Domain | Location | |
|
Multi-stage private equity investments are pursued across diverse sectors.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Abbisko Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Abbisko Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Abbisko Therapeutics Comparisons
Competitors of Abbisko Therapeutics
Abbisko Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Enliven Therapeutics, Nuvalent, Nura Bio, NewAmsterdam Pharma and Skyhawk Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of drugs for solid tumours and blood cancers
|
|
| domain | founded_year | HQ Location |
Therapeutic solutions for cancer, including NSCLC inhibitors, are developed.
|
|
| domain | founded_year | HQ Location |
Diagnostic solutions and neuroprotective medicines for neurological disorders are provided.
|
|
| domain | founded_year | HQ Location |
Therapeutic solutions for cardio-metabolic diseases are developed using obicetrapib.
|
|
| domain | founded_year | HQ Location |
RNA-modifying drug candidates are developed for multiple disorders.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Abbisko Therapeutics
Frequently Asked Questions about Abbisko Therapeutics
When was Abbisko Therapeutics founded?
Abbisko Therapeutics was founded in 2016 and raised its 1st funding round 1 year after it was founded.
Where is Abbisko Therapeutics located?
Abbisko Therapeutics is headquartered in Shanghai, China.
Is Abbisko Therapeutics a funded company?
Abbisko Therapeutics is a funded company, having raised a total of $263M across 4 funding rounds to date. The company's 1st funding round was a Series B of $42M, raised on Feb 05, 2017.
How many employees does Abbisko Therapeutics have?
As of Dec 31, 2024, the latest employee count at Abbisko Therapeutics is 226.
What is the annual revenue of Abbisko Therapeutics?
Annual revenue of Abbisko Therapeutics is $70.36M as on Dec 31, 2024.
What does Abbisko Therapeutics do?
Abbisko therapeutics is developing novel small molecule drugs for immunomodulatory pathways to treat cancer. The companys pipeline has three preclinical candidates. The exact mechanism of action of each moleule has not been disclosed but the company is possibly advancing a STINGTLR activator, IDOCSF1R inhibitor and TGF agonist. The companys integrated RD center locates in the Shanghai Zhangjiang Hi-Tech Park. The company claims to be surrounded by numerous top CRO, CMO and clinical contract organizations in the area, with whom they collaborate o research in drug discovery and development. In the future, the company aims to target other diseases such as liver disease, viral infections and mental disease.
Who are the top competitors of Abbisko Therapeutics?
Abbisko Therapeutics's top competitors include Nuvalent, Enliven Therapeutics and Nura Bio.
Is Abbisko Therapeutics publicly traded?
Yes, Abbisko Therapeutics is publicly traded on HKEX under the ticker symbol 2256.
Who are Abbisko Therapeutics's investors?
Abbisko Therapeutics has 16 investors. Key investors include CICC, The Carlyle Group, Warburg Pincus, Orbimed, and Temasek.
What is Abbisko Therapeutics's ticker symbol?
The ticker symbol of Abbisko Therapeutics is 2256 on HKEX.